4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
Summarize this article with:
SA Transcripts157.39K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential December 17, 2025 8:00 AM EST Company Participants Julian PeiDavid Kirn - Co-Founder, CEO & Director Conference Call Participants Jennifer Taylor-CousarFelix RatjenJonathan Miller - Evercore ISI Institutional Equities, Research DivisionRyan Mcelroy - Leerink Partners LLC, Research DivisionHuidong Wang - Barclays Bank PLC, Research DivisionTommie Reerink - Goldman Sachs Group, Inc., Research DivisionDaniel Giraldo Perez - BofA Securities, Research DivisionYuxi Dong - Jefferies LLC, Research Division Presentation Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to our investor webcast today. As a reminder, today's call is being recorded. With that, I will hand the call over to Julian Pei, Head of Investor Relations, who will make introductory comments.
Julian Pei Good morning, and thank you for joining our webcast to discuss interim Phase I data from our AEROW trial in cystic fibrosis. Before we begin, I encourage everyone to visit our Investor Relations website, where you can find a press release describing this update. A recording of this webcast and presentation materials will also be accessible on the website after the completion of this call. We remind you here, we may be making forward-looking statements. For further details, you can visit our website or our SEC filings. On the call today with prepared remarks will be Dr. David Kirn, our Co-Founder and CEO; Dr. Jennifer Taylor-Cousar from National Jewish Health and Lead Principal Investigator in the AEROW trial; and Dr. Felix Ratjen, Co-Head of the Cystic Fibrosis Center at SickKids Research Institute of the University of Toronto. After the prepared remarks, Kristian Humer, our Chief Financial Officer; and Melissa Calton, our Vice President of Early Stage Product Development, will also join us for Q&A. With